• Molecular NamePregabalin
  • Synonympregabalin
  • Weight159.229
  • Drugbank_IDDB00230
  • ACS_NO148553-50-8
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-0.92
  • pka4.2; 10.6
  • LogD (pH=7, predicted)-0.92
  • Solubility (experiment)Freely soluble
  • LogS (predicted, ACD/Labs)(ph=7)-0.28
  • LogSw (predicted, AB/LogsW2.0)54.11
  • Sw (mg/ml) (predicted, ACD/Labs)82.6
  • No.of HBond Donors3
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds5
  • TPSA63.32
  • StatusFDA approved
  • AdministrationOral(main), IV, Insufflation
  • PharmacologyAn anticonvulsant drug used for neuropathic pain and as an adjunct therapy for partial seizures with or without secondary generalization in adults.
  • Absorption_value90.0
  • Absorption (description)Well absorbed after oral administration.
  • Caco_2N/A
  • Bioavailability90.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNegligible
  • Half life5~6.5 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityIn clinical trials of all patient populations combined, dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and "thinking abnormal" (primarily difficulty with concentration/attention) were more commonly reported by subjects treated with LYRICA than by subjects treated with placebo (≥ 5% and twice the rate of that seen in placebo).
  • LD50 (rat)N/A
  • LD50 (mouse)N/A